Neoadjuvant chemoradiotherapy with serplulimab and nimotuzumab for resectable locally advanced esophageal squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, single-center trial in Tianjin plans to enroll about 46 adults with resectable locally advanced thoracic esophageal squamous cell carcinoma. Participants receive concurrent neoadjuvant chemoradiotherapy (41.4 Gy in 23 fractions) combined with serplulimab (HLX10), nimotuzumab, and chemotherapy. Six to eight weeks after completing neoadjuvant therapy, patients judged operable will undergo radical esophagectomy with postoperative pathological assessment including major pathological response (MPR), pathological complete response (pCR), and pathological response grade. The study will monitor safety and treatment-related adverse events alongside these pathological efficacy endpoints.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Sign an informed consent form.
* Age ≥ 18 years, ≤ 75 years, both genders are eligible.
* Patients with histologically confirmed clinical stage of locally advanced (cT1N2-3M0 or cT2-4aN0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM staging).
* ECOG: 0-1.
* Expected to achieve R0 resection.
* No prior treatment for the primary esophageal tumor, including drug therapy, surgery, and radiotherapy.
* No suspicious metastatic lymph nodes in the neck as suggested by neck enhanced CT or neck ultrasound; no systemic metastasis on imaging studies.
* Measurable lesions according to RECIST 1.1 criteria.
* Important organ functions meet the following requirements:

  1. Absolute neutrophil count ≥ 1.5×10\^9, platelets ≥ 80×10\^9, hemoglobin ≥ 90g/L;
  2. Total bilirubin level ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN (for patients with liver metastasis, AST and ALT levels ≤ 5 times ULN);
  3. Serum creatinine ≤ 1.5 times ULN or creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula);
  4. Serum albumin ≥ 28g/L;
  5. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%);
  6. Pulmonary function: FEV1/FVC ≥ 70%, FEV1 ≥ 50% of normal value, DLCO (diffusing capacity of the lung for carbon monoxide) measured value to predicted value percentage \> 80%.
* Women of childbearing age must agree to use contraception (such as intrauterine device, contraceptive pills, or condoms) during the study and for 6 months after the study ends; negative serum or urine pregnancy test within 7 days before study enrollment, and must be non-lactating patients; men must agree to use contraception during the study and for 6 months after the study ends.
* Must understand and sign the informed consent form.

Exclusion Criteria:

* Within the past six months, received EGFR monoclonal antibodies or EGFR-TKIs.
* Participated in other interventional clinical trials within 30 days prior to screening.
* Have severe comorbidities, such as heart failure, high-risk uncontrollable arrhythmias, severe myocardial infarction, refractory hypertension, renal failure (CKD stage 4 or higher), thyroid dysfunction, mental disorders, diabetes, severe chronic diarrhea (more than 7 bowel movements per day), etc., and those deemed unsuitable for this clinical study by the investigator.
* Patients with brain metastases with symptoms or symptom control for less than 3 months.
* History of other malignancies (except for cured in situ cervical cancer or skin basal cell carcinoma, and other malignancies cured for more than 5 years).
* Presence of active infection or active infectious disease.
* Multifocal esophageal malignant tumors or presence of esophageal fistula or perforation signs.
* Imaging shows tumor invasion of important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the subsequent study period, leading to fatal major bleeding.
* Allergy to the drugs used in this protocol or their components.
* According to the Common Terminology Criteria for Adverse Events (NCI CTCAE V5.0), peripheral neuropathy or hearing loss of grade ≥2.
* Pregnant or breastfeeding women.
* Those with a history of psychiatric drug abuse and unable to quit, or patients with mental disorders.
* Those deemed unsuitable for this study by the investigator.
* Those unwilling to participate in this study or unable to sign the informed consent form.

Where it's running

• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Lei Gong, MD
• Email: leigong@tmu.edu.cn
• Phone: 13820389526

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer

  This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.

  Recruiting at 2 sites Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07739758

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• Low-dose carboplatin with nab-paclitaxel plus delayed serplulimab as first-line therapy for advanced squamous NSCLC

  This trial tests whether giving a low-dose carboplatin and nab-paclitaxel together, with serplulimab started after a delay, helps people with advanced squamous non-small cell lung cancer who have no known targetable gene mutations.

  Recruiting Phase 2 People's Hospital of Quzhou · Quzhou, Zhejiang · NCT07647094

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.